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Amyloid β-protein oligomers upregulate
the β-secretase, BACE1, through a post-
translational mechanism involving its
altered subcellular distribution in neurons
Naomi Mamada1,2, Daisuke Tanokashira1, Ai Hosaka1,2, Fuyuki Kametani3, Akira Tamaoka2 and Wataru Araki1*
Abstract
Background: β-Site amyloid precursor protein cleaving enzyme 1 (BACE1) is a membrane-bound aspartyl protease
that initiates amyloid β-protein (Aβ) generation. Aberrant elevation of BACE1 levels in brains of Alzheimer’s disease
(AD) patients may involve Aβ. In the present study, we used a neuron culture model system to investigate the
effects of Aβ on BACE1 expression as well as the underlying mechanisms.
Results: Rat primary cortical neurons were treated with relatively low concentrations (2.5 μM) of Aβ42 oligomers (Aβ-O)
or fibrils (Aβ-F) for 2–3 days. Aβ-O induced a significant increase in protein levels of BACE1, while Aβ-F only had a
marginal effect. Levels of amyloid precursor protein (APP) and the major α-secretase, ADAM10, remained unaltered
upon treatment with both types of Aβ. Aβ-O treatment resulted in activation of eIF2α and caspase 3 in a time-dependent
manner, with no changes in the endoplasmic reticulum (ER) stress marker, GRP78, indicating that a typical ER stress
response is not induced under our experimental conditions. Furthermore, Aβ-O did not affect BACE1 mRNA expression
but augmented the levels of exogenous BACE1 expressed via recombinant adenoviruses, indicating regulation of BACE1
protein expression, not at the transcriptional or translational but the post-translational level. Immunocytochemical analysis
revealed that Aβ-O causes a significant increase in BACE1 immunoreactivity in neurites (both axons and dendrites), but
not soma of neurons; this change appears relevant to the mechanism of Aβ-O-induced BACE1 elevation, which may
involve impairment of BACE1 trafficking and degradation. In contrast, Aβ-O had no effect on APP immunoreactivity.
Conclusion: Our results collectively suggest that Aβ oligomers induce BACE1 elevation via a post-translational
mechanism involving its altered subcellular distribution in neurons, which possibly triggers a vicious cycle of Aβ
generation, thus contributing to the pathogenetic mechanism of AD.
Keywords: Alzheimer’s disease, Amyloid β-protein, BACE1, Neuron, Oligomer
Background
Alzheimer’s disease (AD) is the most common neurode-
generative dementia characterized by two major patho-
logical hallmarks, extracellular amyloid plaques and
intracellular neurofibrillary tangles composed of amyloid
β-protein (Aβ) and phosphorylated tau protein, respect-
ively [1]. The finding that mutations in familial AD genes
(amyloid precursor protein (APP) and presenilins) affect
Aβ generation to increase total Aβ or the Aβ42/40 ratio
supports the hypothesis that Aβ accumulation plays a cen-
tral role in AD pathology [2]. The longer form of Aβ,
Aβ42, is more aggregable and probably more pathogenic
than Aβ40. Recent evidence further suggests that Aβ olig-
omers, soluble aggregated forms of Aβ, act as an initiator
of AD by inducing the development of tau pathology and
synaptic dysfunction [3, 4]. While the exact toxic forms of
Aβ oligomers and mechanisms underlying their neurotox-
icity remain elusive at present, Aβ oligomers are consid-
ered a viable therapeutic target for AD [3, 4].* Correspondence: araki@ncnp.go.jp1Department of Demyelinating Disease and Aging, National Institute of
Neuroscience, NCNP, Kodaira, Tokyo 187-8502, Japan
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Aβ is a cleavage product of APP by two proteases, spe-
cifically, β-site APP cleaving enzyme 1 (BACE1) and the
γ-secretase complex. APP is initially cleaved by BACE1,
producing secreted APP-β and C-terminal fragment
(CTF) known as β-CTF. β-CTF is subsequently cleaved
by γ-secretase to release Aβ. Alternatively, APP is cleaved
by α-secretase, mainly constituting ADAM10, at the α-site
within the Aβ sequence, precluding Aβ formation [5].
BACE1 is a type I transmembrane aspartyl protease abun-
dantly expressed in neurons in the brain [6]. As a rate-
limiting enzyme for Aβ production, BACE1 is considered
one of the major therapeutic targets for AD [7]. The pro-
tease is matured through the Golgi apparatus and targeted
to the plasma membrane where it is rapidly internalized
to endosomes. As BACE1 activity is optimal at acidic pH,
cleavage of APP occurs predominantly in the endosome.
BACE1 is cycled between the plasma membrane, endo-
somes and the trans-Golgi network (TGN), and mainly
degraded in lysosomes [7, 8].
BACE1 levels and activity are increased in the brains of
AD patients [9–15] and mouse models of AD [15–17],
supporting the involvement of aberrant BACE1 in AD
pathogenesis. In addition, BACE1 expression is reported
to be increased under various stress conditions, such as
ischemia [18, 19]. However, the mechanism underlying
BACE1 increase in AD remains to be defined. It is uncer-
tain whether a direct relationship exists between Aβ and
BACE1, although data supporting an association have re-
cently been described [16]. To elucidate this issue, we in-
vestigated the effects of Aβ (both oligomer and fibril
forms) on BACE1 expression as well as the underlying
mechanisms using a primary neuron culture system. Our
current findings collectively demonstrate that Aβ oligo-
mers induce BACE1 elevation via a post-translational
mechanism involving its altered subcellular distribution.
Results
BACE1 protein levels are increased upon Aβ42 oligomer
treatment
Aβ42 oligomers (Aβ-O) and fibrils (Aβ-F) were prepared
using previously established protocols [20]. Western blot
analysis revealed that the Aβ-O preparation consists
mainly of trimers and tetramers in addition to monomers
and oligomers with molecular sizes of 30–40 kDa, while
Aβ-F is composed of monomers and aggregates that do
not enter the stacking gel (Fig. 1a). Comparable data were
obtained with the two Aβ antibodies, 82E1 and 6E10.
However, 82E1 detected oligomers with higher molecular
sizes more clearly than 6E10.
In designing an experimental protocol, we attempted to
achieve a condition whereby Aβ treatment induces rela-
tively modest neuronal damage, mimicking physiological
conditions. In our pilot experiments, neurons displayed
relatively modest responses to 2.5 μM Aβ-O, which was
therefore employed for further experiments.
To estimate the effects of Aβ on cell survival, the cell
survival assay was performed using Cell Counting Kit-8.
Cell survival remained almost unchanged upon treatment
with Aβ-F, and was only very slightly (10–15 %) decreased
upon Aβ-O treatment on days 2 and 3 (Fig. 1b) compared
with control, suggesting that Aβ induces almost no appar-
ent cell death under our experimental conditions.
Next, we examined the effects of Aβ on BACE1 protein
levels. Primary cortical neurons were treated with 2.5 μM
Aβ-O, Aβ-F or vehicle for 2 or 3 days, followed by Western
blot analysis. Endogenous BACE1 levels in neurons treated
with Aβ-O for 2 or 3 days were significantly increased by
20 and 31 %, respectively, compared with those in control
(Fig. 1c, d). Aβ-F also induced a slight increase in BACE1
protein, but the effect was relatively weaker than Aβ-O.
Data obtained with two different BACE1 antibodies were
almost identical, as shown in Fig. 2c. In contrast, APP pro-
tein levels in neurons treated with Aβ-O or Aβ-F were not
significantly altered, compared with those in control neu-
rons (Fig. 1c, d). Similarly, Aβ-O and Aβ-F did not affect
ADAM10 levels (Fig. 1c, d). Thus, Aβ-O specifically acts to
increase BACE1 protein levels without inducing alterations
in APP and ADAM10.
Aβ oligomers activate caspase 3 and eIF2α
Since Aβ-O induces various cellular responses, including
caspase activation, we analyzed its effects on proteins
related to apoptotic and other stress responses. First, we
examined cleaved caspase 3 (the activated form), an ex-
ecutor molecule in the apoptotic cascade. Levels of
cleaved caspase 3 were significantly increased in neurons
treated with Aβ-O compared with controls, in a time-
dependent manner to 167 and 225 % on days 2 and 3, re-
spectively (Fig. 2a, b). Next, we examined phosphorylated
eIF2α (p-eIF2α), an activated form of the translation initi-
ation factor, eIF2α, that plays an important role in various
stress response pathways. The p-eIF2α/total eIF2α ratio
was significantly increased by 29 and 62 % in Aβ-O-treated
neurons, compared with control, on days 2 and 3, respect-
ively (Fig. 2a, b). In contrast, levels of cleaved caspase 3 and
p-eIF2α/total eIF2α remained almost unaltered in neurons
treated with Aβ-F, compared with controls. As p-eIF2α is
elevated in endoplasmic reticulum (ER) stress, we further
examined the ER stress marker, GRP78. Thapsigargin was
used as a positive control for ER stress. Levels of GRP78
and p-eIF2α/total eIF2α were significantly increased in neu-
rons treated with thapsigargin while GRP78 remained un-
changed in those treated with Aβ-O (Fig. 2c, d). Moreover,
in contrast to Aβ-O, thapsigargin suppressed APP and
BACE1 levels in neurons (Fig. 2c, d). Clearly, the changes
induced by Aβ-O do not result from typical ER stress re-
sponse in our experimental conditions.
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Aβ oligomers induce BACE1 upregulation at the post-
translational level
To ascertain the molecular mechanism underlying the
Aβ-O-induced increase in BACE1 protein, BACE1 mRNA
levels were assessed in neurons treated with Aβ using
semi-quantitative RT-PCR. BACE1 mRNA levels normal-
ized by vimentin were not significantly altered in neurons
treated with Aβ-O or Aβ-F at days 1 and 2 (Fig. 3a, b),
compared with control neurons. These data suggest that
Aβ-O-induced elevation of BACE1 protein is not attribut-
able to alterations in mRNA expression.
Next, we clarified whether the increase in BACE1 pro-
tein levels induced by Aβ-O is translationally regulated.
To this end, we investigated the effects of Aβ-O on ex-
ogenously expressed BACE1. Primary cortical neurons
were infected with recombinant adenoviruses expressing
human BACE1 with a C-terminal rhodopsin tag [21],
and after 1 day, infected cells were treated with Aβ-O
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Fig. 1 Aβ oligomers specifically enhance the BACE1 protein level in primary neurons. a Aβ42 oligomers (O) or fibril (F) preparations (2.3 or 4.5 μg)
were separated with the Tris/Tricine gel, followed by Western blot analysis with anti-Aβ antibodies, 82E1 or 6E10. b Neurons grown on a 12-well
plate were treated with 2.5 μM Aβ as above followed by cell survival assay using the Cell Counting Kit-8, as described in Methods. Relative levels
of cell survival are presented as a graph. Data represent means ± SEM from four separate experiments. c Primary cortical neurons (9DIV) grown on
a six-well plate were treated with 2.5 μM Aβ oligomers (O), fibrils (F) or vehicle (C) for 2 or 3 days, followed by Western blot analysis with antibodies
against BACE1, APP, ADAM10 or β-actin. d Quantitative analysis of BACE1, APP and ADAM10 levels after normalization to β-actin. Data represent
means ± SEM from three or four separate experiments. *p < 0.05, **p < 0.01, compared with control
Mamada et al. Molecular Brain  (2015) 8:73 Page 3 of 12
for 1–3 days. Western analysis with anti-rhodopsin tag
antibody (1D4) disclosed a significant increase in ex-
ogenous BACE1 levels in Aβ-O-treated neurons on day
3 (by ~25 %), compared with control (Fig. 3c, d).
Cleaved caspase 3 levels were additionally increased in
Aβ-O-treated neurons on days 2 and 3, while levels of
APP (~95 % of control) and ADAM10 (~103 % of con-
trol) remained unaffected on day 3 (Fig. 3c). Since ex-
ogenous BACE1 is regulated under the CAG promoter
and does not contain 5’UTR, which is known to be
translationally regulated by p-eIF2α [22], Aβ-O-induced
BACE1 elevation appears independent of translational
regulation via p-eIF2α. The collective data suggest that
the Aβ-O-induced increase in BACE1 protein occurs
through a post-translational mechanism.
Aβ oligomer affects the subcellular distribution of BACE1
To gain further insights into the mechanism underlying
Aβ-O-induced elevation of BACE1, we analyzed the influ-
ence of Aβ-O on intraneuronal localization of BACE1
using immunocytochemistry. In control untreated neu-
rons, endogenous BACE1 immunoreactivity was observed
in neuronal soma and neurites, consistent with recent
findings [23, 24]. Interestingly, in neurons treated with
Aβ-O for 3 days, the intensity of BACE1 immunoreactivity
was higher relative to control, although levels in soma
were comparable between control and Aβ-O-treated neu-
rons (Fig. 4a, c). Further double immunofluorescence
staining with BACE1 and microtubule-associated protein
2 (MAP2) antibodies revealed that Aβ-O treatment trig-
gers increased BACE1 immunoreactivity in both axons
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Fig. 2 Aβ oligomers induce activation of caspase 3 and eIF2α, but do not alter GRP78 levels. a Primary neurons were treated with 2.5 μM Aβ
oligomers (O), fibrils (F) or vehicle (C) for 2 or 3 days, followed by Western blot analysis of cell lysates. Membranes were probed with the
indicated antibodies. b Quantitative analysis of p-eIF2α/total eIF2α ratios and cleaved caspase 3 levels. Data represent means ± SEM from three
separate experiments. *p < 0.05 and **p < 0.01, compared with control. c Primary neurons were treated with 2.5 μM Aβ oligomers (O) for 3 days
or 1 μM thapsigargin (Thap) for 1 day, followed by Western blot as above. Membranes were probed with the indicated antibodies. d Quantitation
of GRP78 levels. Data represent means ± SEM from three independent experiments. **p < 0.01, compared with control
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and dendrites (Fig. 4e). To determine whether this change
in intracellular localization is specific for BACE1, we sub-
sequently analyzed the effect of Aβ-O on APP distribu-
tion. Our data revealed diffuse localization of APP in
soma and neurites, with no significant differences in im-
munoreactivity between control and Aβ-O-treated neu-
rons (Fig. 4b, d). In addition, double immunofluorescence
staining with anti-BACE1 and anti-APP indicated partial
colocalization of their immunoreactivities in both soma
and neurites, the extent of which tended to be increased
in Aβ-O-treated neurons relative to control (Additional
file 1: Figure S1). In view of these findings, we propose
that Aβ-O specifically affects the subcellular distribution
of BACE1 to augment its levels in neuritic compartments.
It is possible that Aβ-O may induce BACE1 accumulation
in neurites by altering BACE1 degradation via lysosomal
pathway, since BACE1 is suggested to be primarily de-
graded via this pathway [7, 8, 23]. We therefore examined
whether lysosomal disturbance leads to abnormal subcellu-
lar distribution of BACE1 by analyzing BACE1 levels and
immunoreactivities in primary neurons treated with a lyso-
somotropic agent chloroquine for 1 day. Western blot ana-
lysis showed that BACE1 protein levels were significantly
increased (~40 %) in chloroquine-treated neurons, com-
pared with control (Additional file 2: Figure S2A). Immuno-
cytochemical analysis revealed that the intensity of BACE1
immunoreactivity was increased significantly in both soma
and neurites of chloroquine-treated neurons, compared
with control (Additional file 2: Figure S2B). Quantitatively,
the extent of BACE1 increment was greater in neurites
(~70 %) than in soma (~40 %) (Additional file 2: Figure
S2C). These results suggest that perturbed lysosomal
degradation results in BACE1 elevation in neurites as
well as soma.
Finally, we examined whether APP processing is affected
by treatment with Aβ-O. To this end, we analyzed APP
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Fig. 3 Aβ oligomers augment BACE1 levels, not at the transcriptional or translational, but the post-translational level. a Total RNA was extracted from
neurons treated with 2.5 μM Aβ oligomers (O), fibrils (F) or vehicle (C) for 1 or 2 days, followed by semi-quantitative RT-PCR. b Band intensities
of BACE1 and vimentin in (A) were quantified, and BACE1 mRNA levels normalized to those of vimentin presented as a graph. Data represent
means ± SEM from three separate experiments. c Primary cortical neurons (8DIV) were infected with recombinant BACE1 adenoviruses expressing
rhodopsin-tagged BACE1. The next day, cells were exposed to Aβ oligomers for 1–3 days, followed by Western blot with anti-rhodopsin tag 1D4.
Membranes were reprobed with the different antibodies specified. d Quantitative analysis of exogenous BACE1 levels. Data represent means ± SEM
from three independent experiments. *p < 0.05, compared with control
Mamada et al. Molecular Brain  (2015) 8:73 Page 5 of 12
CTFs in neurons treated with Aβ-O and/or LY2886721
(LY) [25], a potent BACE1 inhibitor. We found that Aβ-O
induced a significant increase in β’-CTF (probably derived
from alternative BACE1 cleavage between Tyr10 and
Glu11 within the Aβ region) levels, compared to untreated
control, which was inhibited by cotreatment with LY
(Additional file 3: Figure S3). Aβ-O additionally increased
β-CTF levels, although the amounts of β-CTF were much
less than those of β’-CTF. These findings support the view
that Aβ-O promotes amyloidogenic APP processing.
Interestingly, Aβ-O also significantly increased α-CTF
levels, which were further augmented by LY treatment
(Additional file 3: Figure S3).
Discussion
In the current study, we investigated whether Aβ aug-
ments BACE1 expression in neurons and the associated
mechanisms. For this purpose, we established an experi-
mental model in which primary cortical neurons were
treated with relatively low concentrations of Aβ-O or Aβ-
B
A
C
E
1
A
P
P
A
B
C
0
50
100
150
neurite soma
0
50
100
150
axon dendriteF
lu
or
es
ce
nc
e 
in
te
ns
ity
 (
%
)
F
lu
or
es
ce
nc
e 
in
te
ns
ity
 (
%
)
BACE1 BACE1
F
lu
or
es
ce
nc
e 
in
te
ns
ity
 (
%
)
APP
D
Control OligomersControl Oligomers
E
control -O
control
A
A -O
0
20
40
60
80
100
120
neurite soma
*** * **
Fig. 4 Immunocytochemical analysis of BACE1 and APP. a, b Primary cortical neurons grown on coverslips were treated with 2.5 μM Aβ oligomers (Aβ-O)
for 3 days, followed by immunofluorescence staining with anti-BACE1 (a) or anti-APP (b) antibodies. Immunostaining of control and Aβ-O-treated cells was
carried out under the same conditions, and their images were acquired at the same exposure time. Scale bar = 20 μm. Intensity of BACE1 immunoreactivity
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F for relatively long periods that facilitated analysis of cel-
lular responses without obvious cell death, mimicking the
pathological conditions of AD. Using this model, we ini-
tially showed that Aβ-O treatment induces a significant
increase in BACE1 protein levels while Aβ-F produces
only a marginal effect. In contrast, APP and ADAM10
levels remained unaltered, clearly indicating a specific ef-
fect of Aβ-O on BACE1. Our findings are consistent with
previous studies describing Aβ42-induced BACE1 upregu-
lation [16, 26, 27]. For example, Sadleir and Vassar [16]
reported that treatment of mouse primary neurons with
5–10 μM Aβ-O for 1–2 days enhanced BACE1 protein
levels accompanied by elevation of APP. The differential
responses of APP expression to Aβ-O may be attributed
to the species differences of the neurons employed.
Next we focused on the cellular mechanisms by which
Aβ-O elevates BACE1 protein expression. BACE1 mRNA
levels were unaltered by Aβ-O, indicating that elevation is
not regulated at the transcriptional level. Several studies
have demonstrated stimulation of BACE1 transcription
upon Aβ-O treatment in cultured cells other than primary
neurons [19, 26, 28]. In contrast, Sadleir and Vassar [16]
showed no effects of Aβ-O on BACE1 mRNA levels in
mouse primary neurons. These discrepant findings may be
attributed to the different cell types or experimental condi-
tions employed. We further examined whether Aβ-O acts
on post-transcriptional regulation. Interestingly, analysis of
cellular responses to Aβ-O revealed time-dependent induc-
tion of both eIF2α phosphorylation and caspase-3 activa-
tion. Recent studies have indicated that activated eIF2α
increases BACE1 translation under specific conditions, such
as energy deprivation, oxidative stress and viral infection,
although eIF2α activation generally elicits translational at-
tenuation [22, 29, 30]. However, data from the current
study showed that Aβ-O augments the levels of exogen-
ously expressed BACE1, which is independent of p-eIF2α-
mediated translational control, suggesting that Aβ-O regu-
lates BACE1 protein expression not at the translational, but
the post-translational level. Consistently, Sadleir et al. [27]
reported genetic evidence that p-eIF2a is not responsible
for the BACE1 increase in the mouse model of AD. While
endogenous BACE1 was elevated on day 2 following Aβ-O
treatment, we observed an increase in exogenous BACE1
only on day 3. This difference may be due to the gradual
increase in expression of exogenous BACE1 by day 3 mask-
ing the enhancement of BACE1 by Aβ-O via a post-
translational mechanism.
Taken together, the data strongly suggest that Aβ-O el-
evates BACE1 levels via a post-translational mechanism
in our neuron model. To gain further insights into the
mechanism of Aβ-O-mediated BACE1 upregulation, im-
munocytochemical analysis was performed to investigate
the subcellular localization of BACE1. Intriguingly, Aβ-
O treatment induced a significant increase in BACE1
immunoreactivity in neurites, but not soma, while the
immunoreactivity of APP remained unaltered. Consistent
with our findings, BACE1 is reported to accumulate in dys-
trophic neurites surrounding amyloid plaques in brains of
AD patients and AD model mice [15, 23]. The finding that
BACE1 immunoreactivity is enhanced specifically in neur-
ites appears relevant for Aβ-O-mediated BACE1 elevation,
as discussed below. The transport mechanism of BACE1 in
neurites is poorly understood, although a few proteins with
potential roles in the retrograde transport of BACE1 have
been identified [31, 32]. We assume that Aβ-O impairs
BACE1 transport in axons and dendrites via an as yet un-
known mechanism, leading to reduced transport of BACE1
to lysosomal compartments and its augmentation in neur-
ites. In fact, this hypothesis is corroborated by our finding
that chloroquine treatment induces a similar increase in
BACE1 immunoreactivities in neurites, although there is
some difference between the effects of Aβ-O and chloro-
quine on BACE1. Consistently, a previous study reported
that Aβ42 induces upregulation of BACE1 and downregu-
lation of Uch-L1, the latter of which interferes with BACE1
lysosomal degradation in neuronal cells [33]. Stagnation of
BACE1 in neuronal processes may increase the probability
of convergence between BACE1 and APP [34], as implied
by our preliminary data (Additional file 1: Figure S1), pos-
sibly leading to enhancement of amyloidogenic APP pro-
cessing and Aβ generation (Fig. 5). A few molecules are
involved in BACE1 degradation, among which GGA3 has
been most extensively investigated [14, 24, 32, 33]. GGA3
appears to participate in BACE1 sorting from endosomes
to lysosomes, and caspase-mediated depletion of GGA3
stabilizes BACE1 [14, 35]. One hypothesis is that Aβ affects
GGA3. However, our preliminary data indicate that Aβ-O
does not influence GGA3 levels (data not shown). BACE1
sorting between the plasma membrane, endosomes and
TGN appears to be regulated by sorting-associated mole-
cules, such as GGA1, sorting nexin 6 and sortilin [36–38].
Another possibility is that Aβ-O causes dysregulation
of BACE1 sorting, resulting in its augmentation. Fur-
ther studies taking neuronal polarity into consideration
are necessary to elucidate the mechanism of Aβ-O-
induced BACE1 elevation.
In our experiments, treatment with Aβ-O, but not Aβ-F,
led to activation of the eIF2α pathway and the apoptosis
cascade. We observed a significant time-dependent increase
in cleaved caspase 3 in Aβ-O-treated neurons, consistent
with the findings of numerous previous studies [16, 39].
However, despite a marked increase in activated caspase 3,
limited cell death was observed in our experimental model.
It is possible that Aβ-O-induced caspase activation is not
directly associated with cell death, which may have resulted
from the lower Aβ-O concentration used in our experi-
ments. In fact, earlier studies have shown that activation of
caspase 3 does not necessarily correspond to cell death in
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AD brain [40, 41]. P-eIF2α was additionally induced upon
Aβ-O treatment. Consistently, p-eIF2α is reported to in-
crease in the brains of AD patients and AD model mice
[42, 43]. Among the four eIF2α kinases (PERK, PKR,
GCN2, HRI), PERK is known to be activated by ER stress
[44], which is implicated in AD pathology [45–47]. The
PERK pathway may play a major role in the activation of
eIF2α in AD model mice [43, 48]. However, the ER stress
marker protein GRP78 was not increased in Aβ-O-treated
neurons in our study. Furthermore, protein levels of GRP78
and p-eIF2α were increased while those of BACE1 and
APP were decreased in neurons treated with the ER stress
inducer, thapsigargin. Based on these findings, we propose
that typical ER stress does not participate in cellular re-
sponses to Aβ-O in our experimental model.
We have presented evidence that oligomeric Aβ upregu-
lates BACE1 via a post-translational mechanism involving
its altered subcellular localization. Our data also suggest
that Aβ oligomers modulate amyloidogenic APP process-
ing. The present findings imply the direct involvement of
Aβ oligomers in BACE1 elevation in brains of AD patients
and AD model mice. A vicious cycle is proposed to exist
whereby soluble Aβ oligomers augment Aβ production by
promoting amyloidogenic processing of APP through
BACE1 modulation [15, 19]. Thus, Aβ oligomers contrib-
ute to the progression of AD pathology, not only through
its neurotoxicity and synaptotoxicity but also the cycle of
Aβ production via a feed-forward mechanism. Termination
of this vicious cycle may therefore present an effective ap-
proach to prevent pathological progression of AD. To this
end, therapeutic options targeting Aβ oligomers or BACE1
appear promising. Furthermore, the post-translational
mechanisms underlying oligomeric Aβ-induced increase in
BACE1 in neurons remain to be established. Our neuron
model system provides a useful tool to resolve these critical
issues associated with AD pathology.
Conclusion
We used a neuron model system to investigate the effects
of Aβ-O and Aβ-F on BACE1 expression as well as the
underlying mechanisms. The present findings collectively
demonstrated that Aβ-O induces a significant and specific
increase in protein levels of BACE1 via a post-translational
mechanism. Immunocytochemical analysis further re-
vealed that Aβ-O affects the subcellular distribution of
BACE1 to augment its levels in neuritic compartments,
which appears relevant for Aβ-O-mediated BACE1 ele-
vation. We additionally found that Aβ-O induces acti-
vation of eIF2α and caspase 3, with no changes in
GRP78, indicating that typical ER stress does not par-
ticipate in cellular responses to Aβ-O in our experi-
mental model. Thus, a vicious cycle appears to exist
whereby soluble Aβ oligomers promote Aβ production
BACE1
A
Fig. 5 A schema illustrating the mechanism by which Aβ oligomers (Aβ-O) induce BACE1 elevation in neurons. BACE1 levels in neurites, but not
soma, are specifically increased in Aβ-O-treated neurons, compared with untreated control. Aβ-O possibly impairs the trafficking of BACE1 in neurites,
leading to reduced transport to lysosomal compartments and augmentation in neurites. Aberrantly increased BACE1 consequently promotes
Aβ production
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through post-translational modulation of BACE1, con-
tributing to the pathogenetic mechanism of AD.
Methods
Cell culture
Primary cerebral cortical neurons were obtained from
17 day-old embryos of a Wistar rat as described previously
[21, 49]. Neurons were plated on poly-L-lysine-coated
plates or dishes at a density of 680 cells/mm2. Cells were
maintained in a humidified atmosphere of 5 % CO2/95 %
air in Macs Neuro Medium (Miltenyi Biotec, Auburn, CA,
USA) containing 0.5 mM L-glutamine, NeuroBrew-21
(Miltenyi Biotec), and penicillin-streptomycin. Half of the
medium was replaced with fresh medium every 3–4 days.
Antibodies
The following primary antibodies were used in this
study: anti-Aβ (82E1, IBL, Gunma, Japan; 6E10,Covance,
Emeryville, CA, USA), anti-BACE1 (AB5832, Merck
Millipore, Darmstadt, Germany; D10E5, Cell Signaling,
Danvers, MA, USA), anti-APP (R37 [50]; 22C11, Merck
Millipore), anti-ADAM10 (Sigma, St Louis, MO, USA),
anti-phospho-eIF2α (Ser51) (Cell Signaling), anti-eIF2α
(Assay Biotechnology, Sunnyvale, CA, USA), anti-cleaved
caspase 3 (Asp175) (Cell Signaling), anti-GRP78 (BD Bio-
sciences, San Jose, California, USA), anti-β-actin (Sigma),
anti-MAP2 (Merck Millipore), and antibody to the rhod-
opsin tag (1D4) [51] obtained from University of British
Columbia.
Aβ preparation and treatment
Aβ42 oligomers and fibrils were prepared as described
previously [20, 52]. Briefly, human Aβ(1–42) peptide (Pep-
tide Institute, Osaka, Japan) was dissolved in 1,1,1,3,3,3-
hexafluoro-2-propanol (HFIP; Sigma) in a chemical fume
hood to obtain 1 mM solution. HFIP was evaporated over-
night in the hood and further under vacuum for 1 h, and
dried peptide films stored at −30 °C. Prior to use, dried Aβ
peptide was resolved in DMSO to prepare 5 mM stock,
and sonicated in an ultrasonic bath sonicator for 10 min.
To prepare oligomers, 5 mM Aβ DMSO stock was diluted
in DMEM/F12 and left for 1 day at 4 °C. For preparation
of fibrils, Aβ stock was diluted in 0.1 M Tris (pH 7.4) and
shaken for 2 days at room temperature. Immediately be-
fore addition to neurons (9 days in vitro (DIV)), Aβ prepa-
rations were diluted in regular medium and used to
replace the entire medium. Control cultures were treated
with the same concentration of DMSO.
Recombinant adenoviruses
Recombinant adenoviruses expressing BACE1 were pre-
pared using an Adenovirus Dual Expression Vector Kit
(Takara Bio, Shiga, Japan) as described previously [21]. In
recombinant adenoviruses, human BACE1 cDNA with a
C-terminal rhodopsin tag [53, 54] was expressed under
the CAG promoter. To evaluate the effect of Aβ-O on ex-
ogenous BACE1, primary neurons were infected with re-
combinant BACE1 adenoviruses at DIV8. One day after
adenovirus infection, neurons were treated with Aβ-O as
described above, and maintained for 1–3 days.
Cell survival assay
Primary cortical neurons cultured on 12-well plates were
treated with Aβ-O, Aβ-F or vehicle for 2 or 3 days. Cell
Counting Kit-8 solution (Dojindo, Kumamoto, Japan)
was added to each well, and the plates left in a CO2 in-
cubator for 2 h. Absorbance was measured at 450 nm
using a microplate reader. Absorbance of the medium
was subtracted as a blank from that of each sample.
Western blot analysis
Cells were lysed on ice in RIPA buffer (10 mM Tris pH 8.0,
150 mM NaCl, 1%NP-40, 0.5 % sodium deoxycholate,
0.1 % SDS, 5 mM EDTA) containing protease inhibitors
(aprotinin, leupeptin, pepstatin, PMSF) and phosphatase
inhibitors (NaF, Na3VO4). After rocking for 1 h at 4 °C,
samples were centrifuged at 100,000 x g for 30 min, and
the supernatants used as cell lysates. The protein content
in cell lysates was estimated with the bicinchoninic acid
assay (Pierce, Rockford, IL, USA). Samples containing
equal amounts of protein were mixed with 2x Laemmli
sample buffer and incubated at 95 °C for 3 min, followed
by separation on 9 or 12 % polyacrylamide gels and trans-
fer to polyvinylidene difluoride (PVDF) membranes. Blots
were blocked in 5 % non-fat dried milk in phosphate-buffer
saline (PBS) containing 0.05 % Tween-20, and probed with
primary antibodies, followed by secondary peroxidase-
labeled anti-rabbit or mouse IgG. The Can Get Signal Im-
munoreaction Enhancer Solution (Toyobo, Osaka, Japan)
was occasionally incubated with primary antibodies to en-
hance immunoreaction. Protein expression was detected
with a chemiluminescence reagent (Perkin-Elmer, Boston,
MA, USA), and the resulting images examined with a LAS-
1000 (Fuji Film, Tokyo, Japan) image analyzer. β-Actin was
used as the internal control to normalize the levels of pro-
teins of interest.
Analysis of APP CTFs
APP CTFs were analyzed by immunoprecipitation-
Western blotting, as described previously [21]. Briefly,
samples containing an equal amount of protein were
immunoprecipitated with anti-APP antibodies (R37) and
protein G-agarose at 4 °C overnight. The immunopreci-
pitated materials were washed, eluted in 2 x Tris/Tricine
sample buffer, and subjected to Tris/Tricine SDS-PAGE,
followed by Western blot analysis with anti-APP (R37).
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Semi-quantitative reverse transcription (RT)-PCR
Semi-quantitative RT-PCR was essentially performed
using a previously documented protocol [55]. Briefly, total
RNA was extracted from cells using the Gene Elute Mam-
malian Total RNA Miniprep Kit (Sigma). RT was per-
formed in a total reaction volume of 20 μl containing 1 μg
total RNA and 25 μg/ml oligo (dT)15 using the Improm II
Reverse Transcription system (Promega, Madison, WI,
USA), according to the manufacturer’s instructions. For
semi-quantitative RT-PCR, amplification was performed
using 1 μl RT reaction mixture in the presence of 200 μM
dNTPs, 0.5 μM primers, and 1 μl Advantage 2 Polymerase
mix (Stratagene, La Jolla, CA, USA) in a final volume of
50 μl. The primer pairs used were: 5’-ATTCCCTATA
CACTGGCAGTC-3’ and 5’-CCATGACATAGGCTATGG
T-3’ for BACE1, and 5’-GCAGGAGCTGAATGACCGCT
-3’, and 5’-CGGTGAGGTCAGGCTTGGAA-3’ for vimen-
tin. The following PCR conditions were employed: 27 cycles
at 95 °C for 1 min, 60 °C for 1 min, and 72 °C for 1 min for
BACE1, and 25 cycles at 95 °C for 1 min, 64 °C for 1 min,
72 °C for 1 min for vimentin, used as an internal control.
Amplification products were separated on 0.9 % agarose
gels, visualized using ethidium bromide staining, and quan-
tified with an LAS-1000 image analyzer. Under the above
PCR conditions, band intensities of amplified products
were proportional to the amounts of cDNA used in the re-
action, confirming the validity of our analysis.
Immunocytochemistry
Immunocytochemical analysis was essentially performed
as described previously [24]. Primary neurons cultured
on coverslips were fixed with 4 % paraformaldehyde in
PBS. Fixed cells were permeabilized and blocked with
0.3 % Triton X-100 and 1 % horse serum in PBS, and in-
cubated with primary antibody for BACE1 (D10E5) or
APP (22C11) for 1 h, followed by Alexa 488-conjugated
anti-rabbit IgG (Molecular Probes, Eugene, OR, USA)
for 1 h. For double immunofluorescence staining, cells
were subsequently stained with anti-MAP2 antibody and
Alexa568-conjugated anti-mouse IgG (Molecular
Probes). Specimens were examined under an LSM 780
laser scanning confocal microscope (Carl Zeiss, Jena,
Germany). The fluorescence intensities of neurites and
soma were quantified according to previously docu-
mented methods [56]. Briefly, to quantify fluorescence
intensity, 1 pixel-wide line segments were traced along
50 μm of neurites with soma as the starting point. The
mean fluorescence intensity in soma was quantified by
drawing a region around the soma. For each condition,
~20 cells from two different cultures were analyzed. To
distinguish axons and dendrites, cells doubly immuno-
stained with anti-BACE1 and anti-MAP2 were analyzed
as above; an example image is shown in Additional file
4: Figure S4.
Statistical analysis
All results are presented as means ± SEM. Data were sta-
tistically analyzed using one-way analysis of variance
(ANOVA), followed by Bonferroni’s multiple comparison
test or Student’s t-test with a significance threshold of p
< 0.05.
Additional files
Additional file 1: Figure S1. Double immunofluorescence staining with
BACE1 and APP antibodies. Primary cortical neurons were treated with
2.5 μM Aβ-O or vehicle for 3 days, followed by double immunofluorescence
staining with anti-BACE1 and anti-APP antibodies. Scale bar = 20 μm.
(PDF 384 kb)
Additional file 2: Figure S2. Effects of chloroquine on BACE1 levels
and immunoreactivities in primary neurons. (A) Primary neurons were
treated with or without 25 μM chloroquine (CQ) for 1 day, followed by
Western blot analysis with anti-BACE1. Relative levels of BACE1 were
quantified and graphed. Data represent means ± SEM of three samples
from two separate experiments. *p < 0.05, compared with control. (B)
Primary cortical neurons treated with or without 25 μM CQ for 1 day
were immunostained with anti-BACE1. Scale bar = 20 μm. (C) Fluorescence
intensities of BACE1 in soma and neurites in (B) were separately quantified
as described in Methods, and the relative levels depicted on a graph.
(n = 24, ***p < 0.001). (PDF 1277 kb)
Additional file 3: Figure S3. Analysis of APP CTFs in primary neurons.
Primary neurons were treated with either vehicle, 1 μM LY2886721 (LY)
(Selleck Chemicals, Houston, TX, USA), 2.5 μM Aβ-O, or Aβ-O plus LY for
3 days. APP CTFs were analyzed as described in Methods. Relative levels
of β’-CTF and α-CTF were quantified and graphed. Data represent means
± SEM from three separate experiments. **p < 0.01, compared with control.
(PDF 59 kb)
Additional file 4: Figure S4. Quantification of fluorescence intensities
in axons and dendrites. After double immunofluorescent staining of
primary neurons with anti-BACE1 (green) and anti-MAP2 (red) antibodies,
specimens were examined under a LSM780 microscope. BACE1 fluores-
cence intensities along MAP2-positive dendrites (red line) and MAP2-
negative axons (blue line) were quantified as described in Methods. Scale
bar = 10 μm. (PDF 66 kb)
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